What we say and what we mean when we say redundancy and robustness of the chemokine system – how CCR5 challenges these concepts

Classically, robustness and redundancy are features that define the intricate and connected functioning of the chemokine system. Following these ideas, the lack of a particular chemokine or chemokine receptor could be compensated by the presence of other molecules with similar functions, ensuring robustness to the systems. Although these concepts are generally accepted, they represent an oversimplification of a highly complex system that works in a context‐dependent manner. Based on different studies, and taking as an example the chemokine receptor CCR5 (C–C chemokine receptor type 5) and the genetic variant CCR5Δ32, which on several occasions challenge the classical concepts of redundancy and robustness of the chemokine system, we will discuss and question this general and oversimplified point of view.

[1]  A. Antonelli,et al.  Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis. , 2017, Autoimmunity reviews.

[2]  S. Nam,et al.  CCR5 deficiency induces astrocyte activation, Aβ deposit and impaired memory function , 2009, Neurobiology of Learning and Memory.

[3]  A. Mantovani,et al.  Redundancy and robustness versus division of labour and specialization in innate immunity. , 2017, Seminars in immunology.

[4]  M. Sugiyama,et al.  Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients. , 2018, JCI insight.

[5]  L. Vangelista,et al.  The Expanding Therapeutic Perspective of CCR5 Blockade , 2018, Front. Immunol..

[6]  J. Chies,et al.  CCR5 gene editing - Revisiting pros and cons of CCR5 absence. , 2019, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[7]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[8]  R. Nibbs,et al.  A guide to chemokines and their receptors , 2018, The FEBS journal.

[9]  F. Balkwill Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[10]  David Cyranoski,et al.  Genome-edited baby claim provokes international outcry , 2018, Nature.

[11]  G. Graham,et al.  Chemokine Receptor Redundancy and Specificity Are Context Dependent , 2019, Immunity.

[12]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[13]  C. Power Knock out models to dissect chemokine receptor function in vivo. , 2003, Journal of immunological methods.

[14]  Tracy M Handel,et al.  Chemokine: receptor structure, interactions, and antagonism. , 2007, Annual review of immunology.

[15]  T. Schall,et al.  Overcoming hurdles in developing successful drugs targeting chemokine receptors , 2011, Nature Reviews Immunology.

[16]  J. Chies,et al.  Host immunogenetics in tick-borne encephalitis virus infection-The CCR5 crossroad. , 2019, Ticks and tick-borne diseases.

[17]  A. Teixeira-Carvalho,et al.  Analysis of the immunological biomarker profile during acute Zika virus infection reveals the overexpression of CXCL10, a chemokine linked to neuronal damage , 2018, Memorias do Instituto Oswaldo Cruz.

[18]  Gérard Eberl Robustness in living organisms is homeostasis. , 2018, Seminars in immunology.

[19]  H. Lassmann,et al.  CCR5 blockade for neuroinflammatory diseases — beyond control of HIV , 2016, Nature Reviews Neurology.

[20]  A. Rodriguez-Frandsen,et al.  CCR5 deficiency predisposes to fatal outcome in influenza virus infection. , 2015, The Journal of general virology.

[21]  D. Y. Hwang,et al.  CCR5 deficiency accelerates lipopolysaccharide-induced astrogliosis, amyloid-beta deposit and impaired memory function , 2016, OncoTarget.

[22]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[23]  S. Benvenga,et al.  Novel Therapies for Thyroid Autoimmune Diseases , 2016, Expert review of clinical pharmacology.

[24]  P. Tak,et al.  Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[25]  Ting Li,et al.  Pleiotropy Complicates Human Gene Editing: CCR5Δ32 and Beyond , 2019, Front. Genet..

[26]  A. Gholami,et al.  CCR5+T-bet+FoxP3+ Effector CD4 T Cells Drive Atherosclerosis. , 2016, Circulation research.

[27]  E. Lo,et al.  Differential subnetwork of chemokines/cytokines in human, mouse, and rat brain cells after oxygen–glucose deprivation , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  D. McDermott,et al.  CCR5 deficiency increases risk of symptomatic West Nile virus infection , 2006, The Journal of experimental medicine.

[29]  A. Mantovani,et al.  The chemokine system: redundancy for robust outputs. , 1999, Immunology today.

[30]  A. Antonelli,et al.  Chemokines in hyperthyroidism , 2019, Journal of clinical & translational endocrinology.

[31]  Neha S. Gandhi,et al.  Cross-Species Analysis of Glycosaminoglycan Binding Proteins Reveals Some Animal Models Are “More Equal” than Others , 2019, Molecules.

[32]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[33]  D. Weissman,et al.  Reduced Cell Surface Expression of CCR5 in CCR5Δ32 Heterozygotes Is Mediated by Gene Dosage, Rather Than by Receptor Sequestration* , 2002, The Journal of Biological Chemistry.

[34]  W. Ge,et al.  The potential risks of C-C chemokine receptor 5-edited babies in bone development , 2019, Bone Research.

[35]  N. Maeda,et al.  Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. , 2000, The American journal of pathology.

[36]  Hideo Baba,et al.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.

[37]  S. Kunkel,et al.  CCR5 antagonists: the answer to inflammatory disease? , 2006, Expert opinion on therapeutic patents.

[38]  David L. Woodland,et al.  The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. , 2008, Immunity.

[39]  J. Chies,et al.  High CXCL10/IP-10 levels are a hallmark in the clinical evolution of the HIV infection. , 2018, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.